Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles in clinical settings

Submitted by on Thu, 11/06/2025 - 4:11 PM EST

External URL

https://www.acpjournals.org/doi/10.7326/ANNALS-25-01724

ACP Lastest Link Type

Annals of Internal Medicine

Summary

These findings suggest that dulaglutide, semaglutide, and tirzepatide have similar gastrointestinal safety profiles in adults with T2D. This study provides clinicians with evidence to weigh the benefits and risks of these medications.